CASE SERIES

Cà Granda Ospedale Maggiore Policlinico

Andrea Arighi

correpondence
andrea.arighi@policlinico.mi.it

18/06/2022
1 Case Series Description

Age Range: 31-98
Size N: 2181 subjects
Recruitment: from 2012 (10 years)
Data collection: from 2012 (10 years)
Healthy controls: yes (n: 24)
Only at-risk gene carriers included: no (n: 16)
Diseases studied:

- Alzheimer Disease (AD) n: 715
- Subjective Cognitive Complaints (SCC) n: 191
- Mild Cognitive Impairment (MCI) n: 251
- Vascular Dementia (VaD) n: 135
- Frontotemporal Dementia (FTD) n: 228
- Lewy Bodies Dementia (DLB) n: 132
- Parkinson Disease (PD) n: 35
- Progressive Supranuclear Palsy (PSP) n: 18
- Corticobasal Degeneration (CBD) n: 23
- Creutzfeldt-Jakob Disease (CJD) n: 9
- Multiple System Atrophy (MSA) n: 2
- Primary Psychiatric Disorder n: 102
- Mixed dementia n: 265
- Normal Pressure Hydrocephalus n: 28
- Cerebral Amyloid Angiopathy n: 20
- Cerebral Amyloid Angiopathy related inflammation n: 2
- Huntington Disease n: 1

Clinical Evaluation:

- Neurological Assessment
- Neuropsychological Assessment
- Behavioural Assessment

Imaging and Neurophysiology:

- MRI 3 T (n: 782, 441 with advanced MRI sequences)
- FDG-PET (n: 721)
- Amyloid PET (n: 238)
- DaT SPECT (n: 71)
• Myocardial MIBG scintigraphy (n: 4)

Genotyping:
• ApoE for all, C9ORF72 for some, Next Generation Sequencing for some (NGS genes: APOE, APP, ATP13A2, ATP7B, C19orf12, CHCHD10, CHMP2B, CP, CSF1R, DCTN1, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, FTL, FUS, GBA, GFAP, GRN, LRRK2, MAPT, MATR3, NOTCH3, NPC1, NPC2, PANK2, PFN1, PLA2G6, PRKAR1B, PRNP, PSEN1, PSEN2, SNCA, SORL1, SQSTM1, TARDBP, TBK1, TMEM230, TREM2,UBE3A, UBQLN2, VCP)

Digital Data obtained from patients through electronic devices: no

Biological Samples:
• CSF n: 900
• DNA n: 900
• Plasma n: 900
• Serum n: 900

Follow-up:
• Number of Follow-ups planned: from 1 to 10
• Average duration between follow-ups (years): 0.5-1
• Follow-ups type: Clinical and Neuropsychological evaluation